Supportive Therapie mit Zytokinen

  • M. R. Nowrousian
  • O. Kloke

Zusammenfassung

Zytokine sind Polypeptide, die von aktivierten Zellen verschiedenen Typs produziert werden und als intra- und interzelluläre Mediatoren wirken. Sie werden von spezifischen Rezeptoren an der Oberfläche ihrer Zielzellen gebunden und können die Selbsterneuerung, Proliferation, Differenzierung und den Aktivitätszustand dieser Zellen beeinflussen. Sie wirken oft pleotrop und überlappend und häufig auch synergistisch oder additiv. Sie sind außerdem in der Lage, die Produktion und Freisetzung anderer Zytokine zu bewirken. Zu den Zytokinen zählen auch diejenigen Faktoren, die die Hämatopoese regulieren. Dabei handelt es sich um eine Gruppe von Glykopeptiden, die mit unterschiedlichen Schwerpunkten auf die verschiedenen hämatopoetischen Vorläuferzellen und reifen Zellen wirken (Abb. 1). Der Stammzellfaktor stimuliert sowohl die Proliferation der lymphatischen als auch die der myeloischen Vorläuferzellen. Er kann allerdings nur im Synergismus mit einem zusätzlichen Wachstumsfaktor wirken und zu einer starken Proliferation der jeweiligen Zellreihe führen. Das IL-3 (Interleukin-3) stimuliert die Proliferation und Differenzierung der myeloischen Stammzellen und determinierten Vorläuferzellen der Eosinophilen, Basophilen, Megakaryozyten, Granulozyten/Makrophagen und Erythrozyten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Metcalf D (1993) Hematopoietic regulators: redundancy or subtlety? Blood 82:3515–3523PubMedGoogle Scholar
  2. 2.
    Mertelsmann R (1993) Hematopoietic cytokines: from biology and pathophysiology to clinical application. Leukemia 7 (Suppl 2): 168–177Google Scholar
  3. 3.
    Tobler A (1993) Die Bedeutung der Zytokine in der normalen und leukämischen Hämatopoese. Schweiz Med Wochenschr 123:44–52PubMedGoogle Scholar
  4. 4.
    de Sauvage FJ, Hass PE, Spencer SD et al. (1994) Stimulation of megakaryocyto-poiesis and thrombopoiesis by the c-Mpl ligand. Nature 369:533–538PubMedCrossRefGoogle Scholar
  5. 5.
    Bartley TD, Bogenberger J, Hunt P et al. (1994) Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 77:1117–1124PubMedCrossRefGoogle Scholar
  6. 6.
    Bodey GP, Buckley M, Sathe YS et al. (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340PubMedCrossRefGoogle Scholar
  7. 7.
    Harmenberg J, Höglund M, Hellström-Lindberg E (1994) G- and GM-CSF in oncology and oncological haematology. Eur J Haematol 52 (Suppl 55): 1–28Google Scholar
  8. 8.
    Lieschke GJ, Burgess AW (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 327:28–35PubMedCrossRefGoogle Scholar
  9. 9.
    Fleischmann RA (1993) Southwestern internal medicine conference: Clincial use of hematopoietic growth factors. Am J Med Sci 305:248–273CrossRefGoogle Scholar
  10. 10.
    Lieschke GJ, Burgess AW (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 327:99–106PubMedCrossRefGoogle Scholar
  11. 11.
    Gerhartz HH, Engelhard M, Meusers P et al. (1993) Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction tratment of high-grade malignant non-Hodgkin’s lymphomas. Blood 82:2329–2339PubMedGoogle Scholar
  12. 12.
    Kotake T, Miki R, Akaza H et al. (1991) Effect of recombinant granulocyte colony stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer. Cancer Chemother Pharmacol 27:253–257PubMedCrossRefGoogle Scholar
  13. 13.
    de Vries EGE, Biesma B, Willemse PHB et al. (1991) A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 51:116–122PubMedGoogle Scholar
  14. 14.
    Crawford J, Ozer H, Stoller R et al. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170PubMedCrossRefGoogle Scholar
  15. 15.
    Pettengell R, Gurnes H, Radford JA et al. (1992) Granulocyte colony-stimulating factor to prevent doselimiting neutropenia in non-Hodgkin’s lymphoma: A randomized controlled trial. Blood 80:1430–1436PubMedGoogle Scholar
  16. 16.
    Trillet-Lenoir V, Green J, Manegold C et al. (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319–324PubMedCrossRefGoogle Scholar
  17. 17.
    Ogawa M, Masaoka R, Mizoguchi H et al. (1990) A phase III study of KRN 8601 (rhG-CSF) on neutropenia induced by chemotherapy for malignant lymphoma — a multiinstutional placebo controlled double-blind comparative study. Gan To KagakuRyoho 17:365–373PubMedGoogle Scholar
  18. 18.
    Ohno R, Tomonaga M, Kobayashi T et al. (1990) Effect of granulocyte colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 232:871–877CrossRefGoogle Scholar
  19. 19.
    Chung YS, Sowa M, Kato et al. (1991) A clinical study on the effect of recombinant human G-CSF in gastric cancer patients with neutropenia induced by chemotherapy (EAP). J Jpn Soc Cancer Ther 26:802–807Google Scholar
  20. 20.
    Oyama A, Ota K, Asano S et al. (1990) A double-blind, crossover clinical trial of recombinant human G-CSF on neutropenia induced by chemotherapy of non-Hodgkin’s lymphoma. Nippon Gan Chiryo Gakkai Shi 25:2533–2548PubMedGoogle Scholar
  21. 21.
    Kaplan LD, Kahn JO, Crow S et al. (1991) Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma: results of a randomized trial. J Clin Oncol 9:929–940PubMedGoogle Scholar
  22. 22.
    Fukuoka M, Takada M, Masuda N et al. (1992) Dose intensive weekly chemotherapy with or without recombinant human granulocyte colony-stimulating factor (G-CSF in extensive-stage small-cell lung cancer. Proc Am Soc Clin Oncol 11:967Google Scholar
  23. 23.
    Diaz-Rubio E, Adrover E (1994) Use of granulocyte growth factors in solid tumours. Eur J Cancer 30A: 120–122PubMedCrossRefGoogle Scholar
  24. 24.
    Nowrousian MR, Mengelkoch B, Kleine-Herzbruch R et al. (1993) Intensified sequential combination chemotherapy (CEBOPP/VIML), G-CSF and radiotherapy in patients with high-grade malignant non-Hodgkin’s lymphoma (NHL). Ann Hematol 67 (Suppl): 88Google Scholar
  25. 25.
    Anderson JR, Anderson PN, Armitage JO et al. (1994) American Society of Clinical Oncology: recommendations for the use of hematopoietic colony stimulating factors. Evidence-based, clinical practice guidelines. J Clin Oncol 12: 2471–2508Google Scholar
  26. 26.
    The American Society of Clinical Oncology (1996) Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 14:1957–1960Google Scholar
  27. 27.
    Toner G, Woolletl A, Laidlaw C et al. (1994) Low versus standard dose G-CSF prophylaxis after chemotherapy: A randomized, crossover comparison. Proc Am Soc Clin Oncol 13:429Google Scholar
  28. 28.
    Maugard-Louboutin C, Chastang C, Chevallier B et al. (1993) Dose-effect relationship of granulocyte colony-stimulating factor (G-CSF): PE 2601 in patients with advanced breast carcinoma treated by intensive chemotherapy. Proc Am Soc Clin Oncol 12:90Google Scholar
  29. 29.
    Soda H, Oka M, Fukuda M et al. (1996) Optimal schedule for administering colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer. Cancer Chemother Pharmacol 38:9–12PubMedCrossRefGoogle Scholar
  30. 30.
    Crawford J, Kreisman H, Garewal H et al. (1997) The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol 8: 1117–1124PubMedCrossRefGoogle Scholar
  31. 31.
    Niitsu N, Ski S, Muroi K et al. (1997) Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991–96. Br J Cancer 76:1661–1666PubMedCrossRefGoogle Scholar
  32. 32.
    Weintraub M, Adde MA, Venzon DJ et al. (1996) Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 14:935–940PubMedGoogle Scholar
  33. 33.
    Croockewit AJ, Bronchud MH, Aapro MS et al. (1997) A European perspective on hematopoietic growth factors in haemato-oncology: Report of an expert meeting of the EORTC. Eur J Cancer 33:1732–1746PubMedCrossRefGoogle Scholar
  34. 34.
    Chao N, Schriber J, Grimes K et al. (1993) Granulocyte colony-stimulating factor mobilised peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81:2031–2035PubMedGoogle Scholar
  35. 35.
    Ganser A, Seipelt G, Eder M et al. (1992) Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs. Semin Oncol 19 (Suppl 4):95–101PubMedGoogle Scholar
  36. 36.
    Stein RS (1994) Clinical use of growth factors in the myelodysplastic syndromes. Am J Med Sci 307:360–367PubMedCrossRefGoogle Scholar
  37. 37.
    Estey EH (1994) Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 83:2015–2019PubMedGoogle Scholar
  38. 38.
    Moore JO, Dodge RK, Amrein PC et al. (1997) Granulocyte colony- stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoqinone and mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood 89:780–788PubMedGoogle Scholar
  39. 39.
    Dombert H, Chastang C, Fenaux P (1995) A controlled study of recombinant human colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678–1683CrossRefGoogle Scholar
  40. 40.
    Ottmann O, Hoelzer D, Gracien E et al. (1995) Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase III trial. Blood 86:444–450PubMedGoogle Scholar
  41. 41.
    Weite K, Reiter A, Mempel K et al. (1996) A randomized phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 87:3143–3150Google Scholar
  42. 42.
    Pui CH, Boyett JM, Hughes WT et al. (1997) Human granulocyte-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 336:1781–1787PubMedCrossRefGoogle Scholar
  43. 43.
    Costello RT (1993) Therapeutic use of granulocyte-macrophage colony-stimulating factor (GM-CSF). Acta Oncol 32:403–408PubMedCrossRefGoogle Scholar
  44. 44.
    Hammond WP, Proce TII, Souza LM et al. (1989) Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 320:1306–1311PubMedCrossRefGoogle Scholar
  45. 45.
    Weite K, Zeidler C, Reiter A et al. (1990) Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 75:1056–1063Google Scholar
  46. 46.
    Jakubowski AA, Souza L, Kelly F et al. (1989) Effects of human granulocyte colony stimulating factor in a patient with idiopathic neutropenia. N Engl J Med 320:38–42PubMedCrossRefGoogle Scholar
  47. 47.
    Bonilla MA, Gillio AP, Ruggeiro M et al. (1989) Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 320:1574–1580PubMedCrossRefGoogle Scholar
  48. 48.
    Fine KD, Byrd TD, Stone MJ (1997) Successful treatment of chronic severe neutropenia with weekly recombinant granulocyte colony-stimulating factor. Br J Haematol 97:175–178PubMedCrossRefGoogle Scholar
  49. 49.
    Biesma B, de Vries EGE, Willemse PHB et al. (1990) Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur J Cancer 26:932–936PubMedCrossRefGoogle Scholar
  50. 50.
    Riikonen P, Saarinen UM, Mäkipernaa A et al. (1993) rh GM-CSF in the treatment of fever and neutropenia: A double-blind placebo controlled study in children with malignancy. Proc Am Soc Clin Oncol 12:443Google Scholar
  51. 51.
    Masher DW, Lieschke GF, Green M, Bishop J et al. (1994) Filgrastim in patients with chemotherapy induced febrile neutropenia. Ann Intern Med 121:492 – 501Google Scholar
  52. 52.
    Mayordomo Jl, Rivera F, Diaz-Puente MR et al. (1993) Re.: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:1251–1252PubMedCrossRefGoogle Scholar
  53. 53.
    Boogaerts MA (1994) Growth factors in haematology: Prophylactic versus interventional use. Eur J Cancer 30 A:238–243Google Scholar
  54. 54.
    Schimpff SC (1994) Growth factors and empiric therapy with antibiotics: should they be used concurrently? Ann Intern Med 121:538–539PubMedCrossRefGoogle Scholar
  55. 55.
    Klaassen U, Nowrousian MR, Werk S et al. (1993) Sequential antimicrobial therapy for the treatment of infections in neutropenic cancer patients. Ann Hematol 67(Suppl):63Google Scholar
  56. 56.
    Strauss RG (1993) Therapeutic granulocyte transfusions in 1993. Blood 81: 1675–1678PubMedGoogle Scholar
  57. 57.
    Skillings JR, Sridhar FG, Wong C et al. (1993) The frequency of red cell transfusion for anemia in patients receiving chemotherapy. Am J Clin Oncol 16:22–25PubMedCrossRefGoogle Scholar
  58. 58.
    Fernandez Montoya A (1991) Chronic transfusion support. Schweiz Med Wochenschr 121 (Suppl43):106–110Google Scholar
  59. 59.
    Leitgeb C, Pecherstorfer M, Fritz E et al. (1994) Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73: 2535–2542PubMedCrossRefGoogle Scholar
  60. 60.
    Ludwig H, Leitgeb C, Fritz E et al. (1993) Erythropoietin treatment of chronic anaemia of cancer. Eur J Cancer 29 A (Suppl 2): 8–12CrossRefGoogle Scholar
  61. 61.
    Miller CB, Jones RJ, Piantadosi S et al. (1990) Decreased erythropoietin reponse in patients with the anemia of cancer. N Engl J Med 322:1689–1692PubMedCrossRefGoogle Scholar
  62. 62.
    Means RT, Krantz SB (1992) Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80:1639–1647PubMedGoogle Scholar
  63. 63.
    Spivak JL (1994) Cancer-related anemia: its causes and characteristics. Semin Oncol 21(Supl 3):3–8PubMedGoogle Scholar
  64. 64.
    Barosi G (1994) Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 68:215–223PubMedCrossRefGoogle Scholar
  65. 65.
    Krantz SB (1994) Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 307:353–359PubMedCrossRefGoogle Scholar
  66. 66.
    Nowrousian MR, Kasper C, Oberhoff C et al. (1996) Pathophysiology of Cancer-Related Anemia. In: Smyth JF, Boogaerts MA, Ehmer BRM (eds) rhErythro-poietin in Cancer Supportive Treatment. Marcel Dekker, New York Basel Hong Kong, pp 13–34Google Scholar
  67. 67.
    Walker RH (1987) Award lectures and special reports: Transfusion risks. Am J Clin Pathol 88:374–378PubMedGoogle Scholar
  68. 68.
    Klein HG (1994) Immunologic aspects of blood transfusion. Semin Oncol 21 (Suppl 3): 16–20PubMedGoogle Scholar
  69. 69.
    Bergström J (1993) New aspects of erythropoietin treatment. J Intern Med 233: 445–462PubMedCrossRefGoogle Scholar
  70. 70.
    Ludwig H, Fritz E, Kotzmann H et al. (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693–1699PubMedCrossRefGoogle Scholar
  71. 71.
    Oster W, Herrmann F, Gamm H et al. (1990) Erythropoietin for the treatment of anemia of malignancy associated with neoplastic marrow infiltration. J Clin Oncol 8:956–962PubMedGoogle Scholar
  72. 72.
    Yoshida Y, Anzai N, Kawabara H et al. (1993) Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment. Ann Hematol 66:175–180PubMedCrossRefGoogle Scholar
  73. 73.
    Stenke L, Wallvik J, Celsind F et al. (1993) Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 7:1324–1327PubMedGoogle Scholar
  74. 74.
    Abels RI (1992) Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 19 (Supp 8):29–35PubMedGoogle Scholar
  75. 75.
    Abels R (1993) Erythropoietin for anaemia in cancer patients. Eur J Cancer 29 A (Suppl 2): 2–8CrossRefGoogle Scholar
  76. 76.
    Henry DH, Abels RT (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and openlabel follow-up studies. Semin Oncol 21 (Suppl 3):21–28PubMedGoogle Scholar
  77. 77.
    Kasper C, Terhaar A, Fossa A et al. (1997) Recombinant human erythropoietin in the treatment of cancer-related anaemia. Eur J Haematol 58:251–256PubMedCrossRefGoogle Scholar
  78. 78.
    Case DC, Bukowski RM, Carey RW et al. (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85:801–806PubMedCrossRefGoogle Scholar
  79. 79.
    Gamucci T, Thorel MF, Frasca AM et al. (1993) Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin. Eur J Cancer 29A(Suppl 2): 13–14CrossRefGoogle Scholar
  80. 80.
    Cascinu S, Fedeli A, Del Ferro E et al. (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 12:1058–1062PubMedGoogle Scholar
  81. 81.
    Glaspy J, Bukowski R, Steinberg D et al. (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218–1234PubMedGoogle Scholar
  82. 82.
    Tefferi A, Silverstein MN (1994) Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 86:893–896PubMedCrossRefGoogle Scholar
  83. 83.
    Hellström-Lindberg E (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89: 67–71PubMedCrossRefGoogle Scholar
  84. 84.
    Rose EH, Abels RI, Nelson RA et al. (1995) The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 89:831–837PubMedCrossRefGoogle Scholar
  85. 85.
    Bernell P, Stenke L, Wallvik J et al. (1996) A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes. Leuk Res 8:693–699CrossRefGoogle Scholar
  86. 86.
    Negrin RS, Stein R, Doherty K et al. (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. Blood 87: 4076–4081PubMedGoogle Scholar
  87. 87.
    Ludwig H, Fritz E, Leitgeb C et al. (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84:1056–1063PubMedGoogle Scholar
  88. 88.
    Cazzola M, Messinger D, Battistel W et al. (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non- Hodgkin’s lymphoma: Dose finding and identification of predictors of response. Blood 86: 4446–4453PubMedGoogle Scholar
  89. 89.
    Henry D, Thatcher N (1996) Patient selection and predicting response to recombinant human erythropoietin in anemic cancer patients. Semin Hematol 33 (Suppll):2–5PubMedGoogle Scholar
  90. 90.
    Singlbartl G (1994) Adverse events of erythropoietin in long-term and in acute/ short-term treatment. Clin Investig 72:36–43Google Scholar
  91. 91.
    Sunder-Plassmann G, Hörl WH (1994) Iron metabolism and iron substitution during erythropoietin therapy. Clin Investig 72:11–15Google Scholar
  92. 92.
    Adamson JW (1994) The relationship of erythropoietin and iron metabolism to red blood cell production in humans. Semin Oncol 21 (Suppl 3):9–15PubMedGoogle Scholar
  93. 93.
    Aderka D, Praff G, Santo M et al. (1986) Bleeding due to thrombocytopenia in acute leukemias and reevaluation of the prophylactic transfusion policy. Am J Med Sci 291:147–151PubMedCrossRefGoogle Scholar
  94. 94.
    Gmür H, Burger J, Schanz U et al. (1991) Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 338:1223–1226PubMedCrossRefGoogle Scholar
  95. 95.
    Gordon MS, Hoffmann R (1992) Growth factors affecting human thrombo-cytopoiesis: Potential agents for the treatment of thrombocytopenia. Blood 80: 302–307PubMedGoogle Scholar
  96. 96.
    Kaushansky K (1995) Thrombopoietin: The primary regulator of platelet production. Blood 86:419–431PubMedGoogle Scholar
  97. 97.
    Smith JW, Longo DL, Alvord WG et al. (1993) The effects of treatment with inter-leukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med 328:756–761PubMedCrossRefGoogle Scholar
  98. 98.
    D’Hondt V, Weynants P, Humblet Y et al. (1993) Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase lb study. J Clin Oncol 11:2063–2071PubMedGoogle Scholar
  99. 99.
    Veldhuis GJ, Willemse PHB, Sleijfer DT et al. (1995) Toxicity and efficacy of escalating dosages of recombinant interleukin-6 after chemotherapy in patients with breast cancer and non-small-cell lung cancer. J Clin Oncol 13:2585–2593PubMedGoogle Scholar
  100. 100.
    D’Hondt V, Humblet Y, Guillaume Th et al. (1995) Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: A multicentric placebo-controlled, randomized phase Ib study. Blood 85:2347–2353PubMedGoogle Scholar
  101. 101.
    Gordon MS, McCaskill-Stevens WJ, Battiato LA et al. (1996) A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 87:3615–3624PubMedGoogle Scholar
  102. 102.
    Basser RL, Rasko JEJ, Clarke K et al. (1996) Thrombopoietic effects of peg-ylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348:1279–1281PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • M. R. Nowrousian
  • O. Kloke

There are no affiliations available

Personalised recommendations